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Background: Kidney transplantation confers superior outcomes for patients with end stage kidney disease, and live
donor kidneys associate with superior outcomes compared to deceased donor kidneys. Modern immunosuppression
has improved rejection rates and transplant survival and, as a result, recurrence of glomerulonephritis has emerged as
a major cause of allograft loss. However, many glomerulonephritides have significant genetic risk which may manifest
through kidney intrinsic or systemic mechanisms. We hypothesise that heritable kidney intrinsic predisposition to
glomerulonephritis will result in increased risk of glomerulonephritis recurrence in kidneys transplanted from
genetically related donors.
Methods: We investigated the effect of living related donation on rates of recurrence and subsequent graft outcomes
in 7236 patient from 28 years of ANZDATA transplant registry data. Data were analysed in R, using Kaplan Meier
Survival analysis and adjusted analyses performed using Cox Proportional Hazards methods. A competing risk model
was also analysed.
Results: Glomerulonephritis recurrence rates were significantly higher in living related donor grafts compared to either
living unrelated or deceased donor grafts (p < 0 · 001). In IgA nephropathy, transplantation from living related donor
kidneys demonstrated a 10 year recurrence rate of 16 · 7% compared to 7 · 1% in living unrelated donors and 9 · 2%
in deceased donors (HR:1 · 7, 95% CI:1 · 26–2 · 26, p = 0 · 0005 for living related vs deceased donors). In focal segmental
glomerulosclerosis, risk of recurrence at 10 years was 14 · 6% in living related donors compared to 10 · 8% in living
unrelated donors and 6 · 6% in deceased donors (HR:2 · 2, 95% CI 1 · 34–3 · 64, p = 0 · 002) for living related vs deceased
donors. Primary glomerulonephritis death censored graft survival was superior for living donor grafts, related or
unrelated, compared to deceased donor grafts.
Conclusions: We identified a significant increase in the risk of glomerulonephritis recurrence in IgA Nephropathy and
Focal Segmental Glomerulosclerosis in living related donors compared to a deceased donors.
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Kidney transplantation confers the best prognosis [1] for
patients with end stage renal failure and living kidney
donation confers superior outcomes to deceased kidney
donation [2]. However, modern immunosuppression has
substantially improved rejection rates and as a result GN
recurrence is increasingly a major cause of allograft loss* Correspondence: giles.walters@act.gov.au
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of GN may [4, 5] or may not [6, 7] significantly reduce
graft survival with post-transplant GN recurrence the
third most common cause of allograft loss [3, 6, 8].
It has been observed that kidneys transplanted from
living donors have [9] both earlier onset [10–12] and
increased rates [4, 5, 7, 13–17] of GN recurrence. Most
glomerulonephritides have been associated with signifi-
cant genetic risks [9, 10]. It is unclear how this heritability
contributes to disease pathogenesis, with both kidney-
intrinsic [11] or systemic [12] mechanisms implicated.
Equally, it is unclear whether the increased risk of GN
recurrence is due to live donation per se or the presencele is distributed under the terms of the Creative Commons Attribution 4.0
.org/licenses/by/4.0/), which permits unrestricted use, distribution, and
ive appropriate credit to the original author(s) and the source, provide a link to
changes were made. The Creative Commons Public Domain Dedication waiver
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thermore, it is unclear what effect increased recurrence
has on the superior outcomes typically associated with
living related donation. In studies reporting increased risks
of GN recurrence with living related donation, living
related and unrelated graft survival was similar at 5 and
10 years [14, 22], whereas other studies report preserved
survival advantage with living related donation regardless
of GN recurrence [18, 23, 24].
We have investigated the effect of living related dona-
tion on rates of GN recurrence and subsequent graft
outcomes from 28 years of ANZDATA transplant regis-




The Australia and New Zealand Dialysis and Transplant
Registry (ANZDATA) collects data on all renal trans-
plants performed in Australia and New Zealand. Base-
line clinical and demographic data are recorded with
follow up data collected every 6 months from all trans-
plant centres. Patient anonymity is assured with coding
of data on entry. Recurrence of glomerulonephritis is re-
corded in the registry as the date of the relevant biopsy.
Biopsy practice is defined by each centre according to its
current clinical practice. This will necessarily have chan-
ged over the last 30 years with some centres moving to
protocol biopsies. Biopsy indication is not available for
this population currently. Data were extracted from
ANZDATA for all renal allografts transplanted for pa-
tients with a primary GN between 1985 and 2013 within
Australia and New Zealand. Transplants included first,
second, or subsequent transplants. Primary end points
were death censored graft loss (DCGS) or GN recur-
rence until December 2013.
Statistical analyses
All statistical analyses were carried out in R [13]. Base-
line characteristics among groups were assessed using
Pearson’s chi-square test and one way ANOVA. In ana-
lyses of “Primary Glomerulonephritis” we included only
patients with IgA Nephropathy (IGAN), Focal Segmental
Glomerulosclerosis (FSGS), Membranous Nephropathy
(MN) and Mesangiocapillary Glomerulonephritis (MCGN),
excluding those coded with “Other GN”. Survival analyses
were performed in R, using the Surv() function from the
survival library [14] and the npsurv() and survplot() func-
tions from the rms library [15]. Graphs are plotted with
95% confidence intervals. Cox models were constructed to
account for confounding due to differences across groups.
Models adjusted for age, sex, dialysis vintage, HLA mis-
match, peak PRA, total ischemic time and graft number.
Cox proportional hazards ratios (HRs) are calculated usingthe coxph() function from the survival library. Data were
analysed using a competing risk model using the mutually
exclusive outcomes of Death before Recurrence (DbR),
Graft Failure before Recurrence (GFbR) and Recurrence
utilising the Surv() function with type=”mstate”.Results
Baseline demographics
Sixteen thousand twenty-three renal transplants were per-
formed between 1985 and 2013 of which 7,236 (45 · 16%)
were for biopsy-proven primary glomerulonephritis (GN).
Characteristics of the patients are summarised in Table 1.
The most common primary GN was IgA Nephropathy
(IGAN) (33%) followed by Focal Segmental Glomerulo-
sclerosis (FSGS) (13 · 4%). Amongst patients with primary
GN (IGAN, FSGS, Membranous Nephropathy (MN) and
Mesangiocapillary (MCGN) only) 2, 693 (66 · 9%) trans-
plants were from deceased donors, 892 (22 · 2%) from
living related donors and 440 (10 · 9%) were recipients
from living unrelated donors.Increased glomerulonephritis recurrence in allografts
from living related donors
GN recurrence occurred in 424 (10 · 5%) of all primary
GN allografts. GN recurrence rates were significantly
higher in living related donor grafts compared to either
living unrelated or deceased donor grafts (p < 0 · 001)
(Fig. 1). At 10 years, 16 · 2% of living related grafts had
recurrent GN compared to 10 · 3% of living unrelated
and 8 · 9% of deceased donor grafts. There was signifi-
cantly increased risks of GN recurrence with living re-
lated donor kidneys compared with deceased donor
kidneys (HR:1 · 7, 95% CI:1 · 4–2 · 1, p < 0 · 00001) or liv-
ing unrelated donor kidneys (HR: 1 · 6, 95% CI:1 · 05–2 ·
4, p = 0 · 03). A competing risk model was used to com-
pare rates of recurrence in deceased and related donor
allografts. Ten year recurrence rates were slightly
reduced at 7.5% for deceased and 14.8% for related
donors but they remained statistically significant.
These are compared with standard survival analysis
results in Table 2.
IGAN and FSGS demonstrated increased rates of
recurrence associated with living related donation. For
IGAN, living related donor kidneys demonstrated a
10 year recurrence rate of 16 · 7% (recurrence free
survival 83 · 3% (95% CI 79 · 5–87 · 3)) compared to 7 ·
1% (recurrence free survival 92 · 9% (95% CI 87 · 9–98 ·
2)) for living unrelated donors and 9 · 2% (recurrence
free survival 90 · 8 (95% CI 89–92 · 7)) for deceased do-
nors. In adjusted analysis, the risk of IGAN recurrence
was significantly increased for living related donor
kidneys compared to either deceased donor kidneys
(HR:1 · 7, 95% CI:1 · 26–2 · 26, p= 0 · 0005) or living unrelated
Fig. 1 All GNs: recurrence free survival living related vs living unrelated vs deceased
Table 1 Chracteristics of GN Patients by donor category
Deceased Related Unrelated Total P value*
GN Patients 4956 1576 704 7236 0
Other Patients 6201 1686 900 8787
Total 11157 3262 1604 16023
GN patients
Age (Mean, SD) 45.2 (13.4) 35.5 (13.7) 49.4 (12)* 43.6 (15.2) <0.0001
GN Category
FSGS 671 (13.5) 207 (13.1) 97 (13.7) 975 (13.4) <0.0001
IgA 1552 (31.3) 557 (35.3) 284 (40.3) 2393 (33)
MCGN 260 (5.2) 57 (3.6) 31 (4.4) 348 (4.8)
MN 210 (4.2) 71 (4.5) 28 (3.9) 309 (4.2)
Other GN 2263 (45.6) 684 (43.4) 264 (37.5) 3211 (44.3)
Male Gender, n (%) 3311 (66.8) 994 (63) 487 (69.1) 4792 (66.2) <0.005
Caucasian ethnicity, n (%) 4003 (80.7) 1283 (81.4) 586 (83.2) 5872 (81.1) 0.0006
Graft Number, n (%)
Primary 4385 (88.4) 1464 (92.8) 626 (88.9) 6475 (89.4) <0.0001
Secondary 514 (10.3) 100 (6.3) 72 (10.2) 686 (9.4)
Subsequent 57 (1.1) 12 (0.7) 6 (0.8) 75 (1)
Diabetes, n (%) 485 (9.7) 62 (3.9) 45 (6.3) 592 (8.1) <0.0001
Peak panel reactive antibodies (%), Median (IQR) 5 (0–26) 1 (0–10) 0 (0–8) 3 (0–20) <0.001
Total ischaemic time (hrs), Median (IQR) 14 (11–18) 2 (1–3) 2 (1–4) 11 (3–16) <0.001
Zero HLA mismatches, n(%) 219 (4.4) 280 (17.7) 35 (4.9) 534 (7.4%) <0.0001
*p values calculated with Student's t test for continuous variables and Chi squared test for categorical variables
Kennard et al. BMC Nephrology  (2017) 18:25 Page 3 of 9
Table 2 Recurrence rates by standard survival analysis and
competing risk analysis. Mutually exclusive risks of Death before
Recurrence, Graft Failure before Recurrence and Recurrence
were used to construct the competing risk analysis
Competing risk analysis Standard survival analysis
Time (years) Deceased Related Deceased Related
5 4.8 9 5.3 9.4
10 7.5 14.8 8.9 16.2
15 9.3 17.7 11.9 20.3
20 10.2 18.8 14.1 22.1
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(Fig. 2).
In FSGS, living related grafts had an elevated risk of re-
currence at 10 years of 14 · 6% (recurrence free survival
85 · 4%, 95% CI 79 · 6–91 · 6) compared to 10 · 8% among
living unrelated donors (recurrence free survival 89 · 2%,
95% CI 80 · 6–98 · 7) and 6 · 6% in deceased donorsFig. 2 Recurrence free survival in each GN(recurrence free survival 93 · 4% 95% CI 91 · 2–95 · 6).
However, on adjusted analysis, the risk of FSGS recur-
rence in living related donor kidneys was significantly
increased compared only with deceased donor kidneys
(HR:2 · 2, 95% CI 1 · 34–3 · 64, p = 0 · 002) and not with liv-
ing unrelated donor kidneys (HR:1 · 4, 95% CI 0 · 63–3 · 1,
p = 0 · 4). There was no difference in the rates of recur-
rence free survival based on donor category among
patients with MN (p = 0 · 2) or MCGN (p = 0 · 6) (Fig. 2).
Increased glomerulonephritis recurrence in living related
kidney transplants does not impair graft survival
We hypothesised that increased GN recurrence would
have a negative effect on allograft survival and increased
GN recurrence may mitigate the benefits of live donation.
However, for all primary glomerulonephritides death cen-
sored graft survival (DCGS) was superior for live donor
grafts compared to graft survival in deceased donor grafts
(P < 0 · 001) and this survival advantage was maintained in
living related donor grafts (Fig. 3).
Fig. 3 All GN: Death censored graft survival living related vs living unrelated vs deceased
Kennard et al. BMC Nephrology  (2017) 18:25 Page 5 of 9In IGAN, living donor grafts had superior DCGS com-
pared to deceased donor grafts (p = 0 · 002) (Fig. 4). In
contrast, there was no significant difference in MN,
FSGS or MCGN (Fig. 4). In FSGS at 5 and 10 years,
DCGS showed a non-significant trend towards improve-
ment for any live donor kidney (Fig. 4).
We examined graft survival from time of recurrence
(Fig. 5). There was no difference observed in graft sur-
vival of patients with recurrence of GN based on donor
status. At 5 years, DCGS was 41 · 6% (95%CI 35 · 2–49 ·
1) in deceased donor grafts and 52 · 9% (CI 44 · 8-62 · 4)
in living related grafts. Therefore there is no evidence
that living related grafts have more aggressive recurrent
disease than deceased donor grafts.
HLA mismatch does not associate with increased risk of
glomerulonephritis recurrence
We tested whether increased recurrence in IGAN and
FSGS related to shared HLA antigens. The risk of
recurrence was not significantly increased by in zero-
mismatched grafts (Fig. 6). This suggests that the
increased risk of recurrence associated with living re-
lated donation is not due to shared HLA but other
heritable kidney-intrinsic factors.
Discussion
Our study demonstrates an increased risk of primary
GN recurrence within renal allografts from living relateddonors, mainly in patients with IGAN and FSGS. In-
creased risk with live donation has been reported in a
number of studies of primary GN, and specifically in
IGAN [16–21], FSGS [22–24] and MCGN [25–28]. This
is the largest study of primary GN recurrence in trans-
plantation on the effect of living related donation.
Current studies of the effect of donor status on recur-
rence and outcome are unclear. A meta-analysis of the
effect of donor status reported a higher risk of IgA re-
currence in living related grafts but a non-significant
trend in the risk of graft loss [29]. The ERA-EDTA regis-
try analysis [26] reported increased MCGN recurrence,
but equivalent graft survival in living donor grafts,
whether related or not. Other studies have likewise failed
to find an association between live related donation and
GN recurrence [30–33].
The mechanism of increased GN recurrence risk in
living related grafts is unclear. This study implicates
genetic risks for IGAN and FSGS manifesting in a
kidney-intrinsic manner. However, it remains unclear if
recurrence of IGAN is [34, 35] or is not [32, 36] more
frequent in transplants with zero HLA mismatches. In
this study we did not identify an elevated risk due to
HLA, suggesting an alternative genetic mechanism. This
study cannot exclude a role for minor HLA antigens.
Despite the elevated risk of GN recurrence demon-
strated in grafts from living related donors, death-
censored graft survival was still superior for patients
Fig. 4 Death censored graft survival living related vs living unrelated vs deceased
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ence was observed in death-censored graft survival in
MN, FSGS or MCGN. Our study shows that, for those
with a primary diagnosis of IGAN or FSGS, the benefit
of live allograft donation is maintained regardless of the
elevated risk of GN recurrence. This benefit does not ap-
pear to be present for patients with membranous or
MCGN. Therefore, increased recurrence rates do not out-
weigh the superior outcomes associated with living dona-
tion, in agreement with previous studies [5, 7, 19, 26].
Based on our observations, live donor allografts remain
the standard for transplantation in primary GN.
Whilst this is a large, well-characterised study population
with 28 years follow-up, we acknowledge the limitations
inherent in registry analysis. Despite these limitations, this
study represents the most complete and well-populated
registry analysis to date.
The increasing use of protocol biopsies post trans-
plantation has the potential to alter the results of this
analysis. The significance of histological evidence ofrecurrence in the absence of clinical evidence of glomer-
ulonephritis is unclear. It may be argued that to
adequately document the incidence and prevalence of
post-transplant GN, a protocol biopsy regimen should
be mandatory. Under those circumstances, it is highly
likely that the GN recurrence rate would rise, but the
overall impact on graft survival may fall. Whilst this
might increase scientific rigour, it remains to be shown
that such a policy can improve outcomes, both for
recurrent GN and graft survival.
Conclusions
In this Registry analysis of 7,236 patients with primary
glomerulonephritis who received renal allografts be-
tween 1985 and 2013 we identified a significant increase
in the risk of GN recurrence in patients suffering from
IGAN and FSGS where donation occurs from a living
related donor compared to a deceased donor. Despite
this elevated risk of recurrent disease, the survival
advantage of living related donation is maintained. We
Fig. 5 Death censored graft survival in grafts with recurrent disease living related vs unrelated from time of recurrence
Fig. 6 Recurrence free survival by HLA matching in living related or living unrelated grafts
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Kennard et al. BMC Nephrology  (2017) 18:25 Page 8 of 9conclude that there is no reason to avoid living related
donation in recipients with primary GN despite the
elevated risks. Potential recipients should, however, be
informed of the increased risk of disease recurrence
when receiving an organ from a relative.
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